Hims Semaglutide Review (2026): Compounded vs Brand & Cost

If you searched "Hims semaglutide review," you are almost certainly trying to figure out one thing: is the cheap monthly "semaglutide" that Hims & Hers advertises the same as Wegovy, and is it safe? The honest answer requires untangling a model that became one of the most controversial stories in the GLP-1 market. Hims & Hers built its weight-loss business heavily on compounded semaglutide — not the FDA-approved brand product — and that model came under intense pressure after the FDA declared the semaglutide shortage resolved in early 2025. This review explains what Hims actually sells, what changed, what it costs, and the safety and legitimacy questions you should ask before subscribing — all as of June 2026. Verify current offerings and pricing directly; nothing here is medical or financial advice, and we earn nothing by steering you to or from any platform.

Quick answer: what is Hims selling?

Hims & Hers is a large, publicly traded telehealth company — legitimate as a business. The nuance is the product. For most of its GLP-1 ramp, the headline "semaglutide from ~$199/month" offer was compounded semaglutide, mixed by a pharmacy, not branded Wegovy or Ozempic. Compounded drugs are not FDA-approved, are not reviewed for safety and efficacy the way the brand product is, and can vary in concentration and quality between batches. That is the single most important thing to understand: a cheap "Hims semaglutide" subscription historically was not the same regulated product the clinical trials studied. We cover the regulatory backdrop in full in is compounded semaglutide still legal in 2026?.

What changed: the 2025 compounding wind-down

Compounded semaglutide was broadly legal mainly because semaglutide sat on the FDA's drug-shortage list — that listing let pharmacies make copies to fill the gap. The FDA declared the shortage resolved on February 21, 2025, then gave compounders a short wind-down (state-licensed 503A pharmacies to late April, larger 503B outsourcing facilities to late May 2025). After that, routinely compounding "essentially a copy" of approved semaglutide is no longer covered by the shortage exception. This squeezed the entire compounded-GLP-1 business — Hims included — and there was significant public friction, including a high-profile falling-out between Hims and Novo Nordisk over how compounded semaglutide was being marketed and sold. The practical upshot for a 2026 shopper: any platform still foregrounding cheap "compounded semaglutide" deserves hard questions about exactly what you'd receive and under what clinical justification.

What Hims costs

As of June 2026, Hims has historically marketed its compounded GLP-1 offerings starting around ~$199/month (often requiring a multi-month commitment), with branded options and other GLP-1 medications priced higher. Two honest caveats on that headline:

• •The cheap number usually referred to the compounded product, not brand Wegovy/Ozempic. Post-wind-down, confirm precisely what is being shipped.
• •Watch for fee stacking and commitment terms. Telehealth headline prices often assume a specific dose, a prepaid multi-month plan, or exclude separate consultation/membership charges. Compute your true all-in monthly cost at your maintenance dose. Our Wegovy & Ozempic cost calculator does that math, and we lay out every payment route — savings card, NovoCare self-pay, GoodRx, compounded — in Wegovy cost and savings.

By comparison, the legitimate brand-cash route, Novo Nordisk's own NovoCare self-pay channel, has run around ~$499/month for brand-name Wegovy vials as of June 2026 — more than the compounded headline, but it is the actual FDA-approved product.

Is Hims semaglutide safe?

This is the crux. The semaglutide molecule — when it's the FDA-approved brand product — has a deep evidence base. In STEP 1, adults lost about 15% of body weight on once-weekly semaglutide 2.4 mg over 68 weeks versus roughly 2.4% on placebo¹, and SELECT showed semaglutide cut major cardiovascular events in people with established heart disease and obesity without diabetes². But those trials studied brand-name semaglutide. Compounded versions are a different proposition:

• •They are not FDA-approved and not individually reviewed for safety, efficacy, or manufacturing quality.
• •The FDA and poison-control centers flagged dosing errors during the compounding boom — partly because compounded products often come as vials requiring you to measure and draw your own dose, which is more error-prone than a pre-measured pen.
• •Some compounded products used salt forms (semaglutide sodium/acetate) that are not the same as the approved active ingredient — a specific FDA concern.

None of this means every compounded dose is dangerous, but it does mean you are trading regulatory oversight for price. If you go the compounded route, knowing how to measure and inject correctly matters more, not less — see how to inject Wegovy and the best place to inject semaglutide.

What people commonly report

Synthesizing recurring review themes honestly: many users report real weight loss on Hims' GLP-1 program (consistent with what semaglutide does generally), praise the convenience and low headline price, and find the sign-up easy. The recurring complaints cluster around uncertainty about what they're actually getting (compounded vs brand), billing and cancellation friction with the subscription model, and dose/vial confusion. As always, online reviews are self-selected and unverified — and a review of a compounded product tells you little about branded Wegovy. We explain how to read these critically in Wegovy reviews: what users and the trials report.

Who Hims suits — and who should be cautious

Hims may suit someone who wants a low-friction, lower-cost telehealth GLP-1 program and who has done the homework on exactly what product they'll receive and is comfortable with a vial-and-syringe format. Be cautious if you assumed the cheap price meant brand Wegovy, if you're uneasy taking a non-FDA-approved compounded product, or if you want the standardized pen and oversight of the brand drug — in which case NovoCare self-pay or an insurance-covered brand route is the safer bet. We rank legitimate options on price and oversight in our independent best semaglutide providers guide.

The bottom line

Hims & Hers is a legitimate company, but its cheap "semaglutide" headline has historically meant compounded semaglutide — not the FDA-approved brand drug the trials studied — and that model was squeezed hard by the 2025 shortage wind-down. The molecule works (about 15% average loss in STEP 1; cardiovascular benefit in SELECT), but compounded versions trade FDA oversight, standardized dosing, and a pre-measured pen for a lower price. Before subscribing, confirm exactly what product you'd receive, compute the all-in cost at your dose, and weigh the compounded route's documented dosing-error and quality concerns. For the full evidence picture, start with our pillar, Semaglutide: how it works, results and side effects; for the safer brand routes, see best places to get Wegovy online. Figures here are as of June 2026 — verify before you buy.